MiNK Therapeutics (INKT) Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
INKT Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
MiNK Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.50 |
| 52 Week High | US$76.00 |
| 52 Week Low | US$4.56 |
| Beta | 0.34 |
| 1 Month Change | 4.60% |
| 3 Month Change | -11.94% |
| 1 Year Change | 41.42% |
| 3 Year Change | -45.41% |
| 5 Year Change | n/a |
| Change since IPO | -89.58% |
Recent News & Updates
Recent updates
MiNK Therapeutics, Inc.'s (NASDAQ:INKT) Intrinsic Value Is Potentially 18% Below Its Share Price
Mar 05
MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely
Oct 26Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?
Jun 28Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?
Mar 18MiNK Therapeutics GAAP EPS of -$0.18
Aug 16MiNK Therapeutics GAAP EPS of -$0.18
Aug 09MiNK Therapeutics A Bargain For Potential Cell Therapies
Jun 23We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely
May 05Shareholder Returns
| INKT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.5% | 3.6% | -0.4% |
| 1Y | 41.4% | 26.9% | 12.7% |
Return vs Industry: INKT exceeded the US Biotechs industry which returned 26.9% over the past year.
Return vs Market: INKT exceeded the US Market which returned 12.7% over the past year.
Price Volatility
| INKT volatility | |
|---|---|
| INKT Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INKT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INKT's weekly volatility has decreased from 105% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 23 | Jen Buell | minktherapeutics.com |
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases.
MiNK Therapeutics, Inc. Fundamentals Summary
| INKT fundamental statistics | |
|---|---|
| Market cap | US$58.68m |
| Earnings (TTM) | -US$12.36m |
| Revenue (TTM) | n/a |
Is INKT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INKT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$12.36m |
| Earnings | -US$12.36m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -42.4% |
How did INKT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/26 18:50 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MiNK Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |
| Maneka Mirchandaney | Evercore ISI |